RECRUITING

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Description

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

Conditions

Solid Tumors
Talk to us

Related Conditions:

Solid Tumors

Study Overview

On this page

Study Details

Study overview

The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Condition
Solid Tumors
Intervention / Treatment

-

Contacts and Locations

San Antonio

Exelixis Clinical Site #1, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • * Minimum life expectancy of ≥ 12 weeks.
  • * Recurrent locally advanced or metastatic solid tumors.
  • * Adequate end organ and bone marrow function.
  • * Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.
  • * History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
  • * Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
  • * Known history of immunodeficiency virus (HIV) unless specific criteria are met.
  • * Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody.
  • * Major surgery within 4 weeks before the first dose of study treatment.
  • * Received radiation therapy within 2 weeks before the first dose of study treatment.
  • * Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study treatment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Exelixis,

Study Record Dates

2028-02